Pfizer (PFE) Short-Term Debt repayments (2013 - 2025)

Pfizer (PFE) has 13 years of Short-Term Debt repayments data on file, last reported at $151.0 million in Q2 2025.

• Quarterly Short-Term Debt repayments fell 96.66% year-over-year to $151.0 million in Q2 2025, while the trailing twelve-month figure through Mar 2026 was $151.0 million (down 98.97% YoY) and the FY2025 annual result came in at $2.2 billion, down 80.41% from the prior year.
• Short-Term Debt repayments declined to $151.0 million in Q2 2025 per PFE's latest filing, from $2.0 billion in the prior quarter.
• Across five years, Short-Term Debt repayments topped out at $7.8 billion in Q3 2024 and bottomed at $1.0 million in Q4 2021.
• The 5-year median for Short-Term Debt repayments is $1.2 billion (2024), against an average of $2.3 billion.
• The widest annual swing landed in 2021, when Short-Term Debt repayments tumbled 99.99%; it then soared 388600.0% in 2022.
• Tracing PFE's Short-Term Debt repayments over 5 years: stood at $1.0 million in 2021, then soared by 388600.0% to $3.9 billion in 2022, then tumbled by 99.92% to $3.0 million in 2023, then soared by 259033.33% to $7.8 billion in 2024, then tumbled by 98.06% to $151.0 million in 2025.
• Per Business Quant, the three latest PFE Short-Term Debt repayments figures stand at $151.0 million (Q2 2025), $2.0 billion (Q1 2025), and $7.8 billion (Q3 2024).

Peer Comparison